Tim Brier
Research Subjects
Tim Brier has a total of 60 co-authors. Here are the top co-authors by number of shared publications:
- Ali Saleh
Oncology Targeted Discovery-Drug CandidateDC, Chemistry, AstraZeneca, London E1 2AX, UK
17 shared publications - Alma Andoni
AstraZeneca, Gaithersburg, Maryland
17 shared publications - Ana De Almeida
AstraZeneca, Waltham, Massachusetts
17 shared publications - Benedicte Recolin
AstraZeneca, Cambridge, United Kingdom
17 shared publications - Christopher Ward
AstraZeneca, Gaithersburg, Maryland
17 shared publications - Claire Myers
AstraZeneca, Gaithersburg, Maryland
17 shared publications
Latest Publications
- Open Access
- 20 January 2026
- Published by Wiley in Clinical and Translational Science
- Vol. 19 (2) , e70475
Open‐Label Study Assessing Relative and Absolute Bioavailability of Oral Camizestrant Formulations and Food Effects in Healthy Postmenopausal Women
Camizestrant is the next‐generation oral selective estrogen receptor degrader and complete estrogen receptor antagonist in Phase 3 development for hormone receptor‐positive breast cancer. To investigate the impact of manufacturing changes during pivotal Phase 3 studies, this open‐label, randomized crossover study of 32 postmenopausal healthy volunteers determined the relative bioavailability of a tablet used in early clinical studies (Phase 1 tablet), a tablet designed for late‐phase development (prototype Phase 3 tablet), and an oral solution. Absolute oral bioavailability in the fasted state (using a [ 14 C] camizestrant intravenous microtracer) and effects of a high‐fat meal on the prototype Phase 3 tablet were also determined. The geometric mean ratios (GMRs) of the prototype Phase 3/Phase 1 tablets (% [90% CI]) for C max and AUC, respectively were 98.7 (87.4–111.5) and 97.4 (92.6–102.5) at 75 mg ( n = 15), and 96.6 (86.9–107.5) and 100.4 (96.2–104.9) at 300 mg ( n = 15). GMRs of the prototype Phase 3 tablet/oral solution for C max and AUC were 96.2 (85.3–108.7) and 99.5 (94.6–104.6) at 75 mg ( n = 15). Fed‐to‐fasted C max and AUC GMRs were 106.2 (94.3–119.7) ( n = 16) and 109.8 (104.4–115.5) ( n = 15) at 75 mg ( n = 16), and 115.9 (104.3–128.7) and 102.3 (98.0–106.8) at 300 mg ( n = 15). Absolute oral bioavailability at 75 mg ( n = 6) and 300 mg ( n = 6) was 42.5% (36.8%–49.0%) and 55.1% (48.5%–62.5%). The formulations showed similar exposures, supporting the planned manufacturing changes. Camizestrant exhibited moderate bioavailability; exposures were similar under fasted and high‐fat meal conditions, supporting its administration with or without food.
- 20 January 2026
- Published by Wiley in Clinical and Translational Science
- Vol. 19 (2) , e70475
Open AccessOpen‐Label Study Assessing Relative and Absolute Bioavailability of Oral Camizestrant Formulations and Food Effects in Healthy Postmenopausal Women
Camizestrant is the next‐generation oral selective estrogen receptor degrader and complete estrogen receptor antagonist in Phase 3 development for hormone receptor‐positive breast cancer. To investigate the impact of manufacturing changes during pivotal Phase 3 studies, this open‐label, randomized crossover study of 32 postmenopausal healthy volunteers determined the relative bioavailability of a tablet used in early clinical studies (Phase 1 tablet), a tablet designed for late‐phase development (prototype Phase 3 tablet), and an oral solution. Absolute oral bioavailability in the fasted state (using a [ 14 C] camizestrant intravenous microtracer) and effects of a high‐fat meal on the prototype Phase 3 tablet were also determined. The geometric mean ratios (GMRs) of the prototype Phase 3/Phase 1 tablets (% [90% CI]) for C max and AUC, respectively were 98.7 (87.4–111.5) and 97.4 (92.6–102.5) at 75 mg ( n = 15), and 96.6 (86.9–107.5) and 100.4 (96.2–104.9) at 300 mg ( n = 15). GMRs of the prototype Phase 3 tablet/oral solution for C max and AUC were 96.2 (85.3–108.7) and 99.5 (94.6–104.6) at 75 mg ( n = 15). Fed‐to‐fasted C max and AUC GMRs were 106.2 (94.3–119.7) ( n = 16) and 109.8 (104.4–115.5) ( n = 15) at 75 mg ( n = 16), and 115.9 (104.3–128.7) and 102.3 (98.0–106.8) at 300 mg ( n = 15). Absolute oral bioavailability at 75 mg ( n = 6) and 300 mg ( n = 6) was 42.5% (36.8%–49.0%) and 55.1% (48.5%–62.5%). The formulations showed similar exposures, supporting the planned manufacturing changes. Camizestrant exhibited moderate bioavailability; exposures were similar under fasted and high‐fat meal conditions, supporting its administration with or without food.
- Open Access
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Derivation of AZD5335, a Novel FRα-Targeted TOP1i-Loaded ADC, for the Treatment of FRα-Expressing Cancers
AZD5335 Pharmacokinetic Parameters
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Derivation of AZD5335, a Novel FRα-Targeted TOP1i-Loaded ADC, for the Treatment of FRα-Expressing Cancers
AZD5335 Pharmacokinetic Parameters
- Open Access
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S6 from Derivation of AZD5335, a Novel FRα-Targeted TOP1i-Loaded ADC, for the Treatment of FRα-Expressing Cancers
AZD5335 Statistical Analyses [Figure 4]
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S6 from Derivation of AZD5335, a Novel FRα-Targeted TOP1i-Loaded ADC, for the Treatment of FRα-Expressing Cancers
AZD5335 Statistical Analyses [Figure 4]
- Open Access
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Derivation of AZD5335, a Novel FRα-Targeted TOP1i-Loaded ADC, for the Treatment of FRα-Expressing Cancers
AZD5335 Statistical Analyses [Figure 1]
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Derivation of AZD5335, a Novel FRα-Targeted TOP1i-Loaded ADC, for the Treatment of FRα-Expressing Cancers
AZD5335 Statistical Analyses [Figure 1]
- Open Access
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Derivation of AZD5335, a Novel FRα-Targeted TOP1i-Loaded ADC, for the Treatment of FRα-Expressing Cancers
Assessment of AZD5335/TOP1i-mediated DDR.
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Derivation of AZD5335, a Novel FRα-Targeted TOP1i-Loaded ADC, for the Treatment of FRα-Expressing Cancers
Assessment of AZD5335/TOP1i-mediated DDR.
- Open Access
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Derivation of AZD5335, a Novel FRα-Targeted TOP1i-Loaded ADC, for the Treatment of FRα-Expressing Cancers
Characterization of FRa mAb INT-019 (mAb49).
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Derivation of AZD5335, a Novel FRα-Targeted TOP1i-Loaded ADC, for the Treatment of FRα-Expressing Cancers
Characterization of FRa mAb INT-019 (mAb49).
- Open Access
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S7 from Derivation of AZD5335, a Novel FRα-Targeted TOP1i-Loaded ADC, for the Treatment of FRα-Expressing Cancers
AZD5335 Statistical Analyses [Figure 5]
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S7 from Derivation of AZD5335, a Novel FRα-Targeted TOP1i-Loaded ADC, for the Treatment of FRα-Expressing Cancers
AZD5335 Statistical Analyses [Figure 5]
- Open Access
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Derivation of AZD5335, a Novel FRα-Targeted TOP1i-Loaded ADC, for the Treatment of FRα-Expressing Cancers
AZD5335-related intra-tumoral pharmacodynamic analyses.
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Derivation of AZD5335, a Novel FRα-Targeted TOP1i-Loaded ADC, for the Treatment of FRα-Expressing Cancers
AZD5335-related intra-tumoral pharmacodynamic analyses.
- Open Access
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Derivation of AZD5335, a Novel FRα-Targeted TOP1i-Loaded ADC, for the Treatment of FRα-Expressing Cancers
Assessment of AZD5335-associated bystander activities.
- 15 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Derivation of AZD5335, a Novel FRα-Targeted TOP1i-Loaded ADC, for the Treatment of FRα-Expressing Cancers
Assessment of AZD5335-associated bystander activities.